Changeflow GovPing Pharma & Drug Safety PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERI...
Routine Notice Added Final

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES (EP3244930A1)

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office granted patent EP3244930A1 to the University of Southern California covering pharmaceutical compositions comprising POH derivatives with anti-cancer properties. The patent names Thomas Chen, Daniel Levin, and Satish G. Pupalli as inventors. The patent is classified under A61P 35/00 (antineoplastic agents) and designates all European member states including DE, FR, GB, IT, ES, and NL.

What changed

The European Patent Office published patent application EP3244930A1 for the University of Southern California covering pharmaceutical compositions containing POH derivatives for anti-cancer applications. The patent includes claims related to heterocyclic compounds (C07D classifications) and therapeutic compositions (A61K, A61P 35/00). The designated states cover all European Patent Convention member countries.

Pharmaceutical companies and research institutions developing cancer therapeutics should review this patent for freedom-to-operate considerations and potential licensing opportunities. Patent holders should monitor maintenance fee deadlines to preserve patent rights in desired jurisdictions.

What to do next

  1. Monitor patent maintenance deadlines

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

Publication EP3244930A1 Kind: A1 Apr 08, 2026

Applicants

University of Southern California

Inventors

CHEN, Thomas, LEVIN, Daniel, PUPALLI, Satish G.

IPC Classifications

A61K 31/415 20060101AFI20251120BHEP A61K 47/54 20170101ALI20251120BHEP A61K 47/55 20170101ALI20251120BHEP C07D 207/26 20060101ALI20251120BHEP A61K 31/4015 20060101ALI20251120BHEP C07D 487/04 20060101ALI20251120BHEP C07D 231/12 20060101ALI20251120BHEP A61N 5/10 20060101ALI20251120BHEP A61K 9/00 20060101ALI20251120BHEP A61K 45/06 20060101ALI20251120BHEP A61P 35/00 20060101ALI20251120BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Pharmaceutical Compositions POH Derivatives Anti-Cancer Applications

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3244930A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Anti-cancer therapeutics Pharmaceutical R&D
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!